| Trial ID: | L2979 |
| Source ID: | NCT05870462
|
| Associated Drug: |
Semaglutide Pen Injector
|
| Title: |
Semaglutide and Vascular Regeneration
|
| Acronym: |
SEMA-VR
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Atherosclerosis|Cardiovascular Diseases|Diabetes Mellitus, Type 2|Obesity
|
| Interventions: |
DRUG: Semaglutide Pen Injector
|
| Outcome Measures: |
Primary: Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months, Baseline to 6 months post-randomization | Secondary: Changes in the mean frequency (%) of circulating ALDHhiSSCmid pro-vascular monocytes in individuals treated with semaglutide versus usual care for 6 months, Baseline to 6 months post-randomization|Changes in the frequency (%) of circulating ALDHhiSSCmid pro-inflammatory monocytes in individuals treated with semaglutide versus usual care for 6 months, Baseline to 6 months post-randomization|Changes in the frequency (%) of circulating ALDHhiSSChi pro-inflammatory granulocyte precursors in individuals treated with semaglutide versus usual care for 6 months, Baseline to 6 months post-randomization
|
| Sponsor/Collaborators: |
Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group | Collaborators: Unity Health Toronto|Western University, Canada
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2023-04-29
|
| Completion Date: |
2024-12
|
| Results First Posted: |
|
| Last Update Posted: |
2023-07-25
|
| Locations: |
North York Diagnostic and Cardiac Centre, North York, Ontario, M6B 1N6, Canada|Diagnostic Assessment Centre, Scarborough, Ontario, M1S4N6, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT05870462
|
